• $120.7M
    Market Cap
  • -38.02%
    1-Year Change
  • Biotechnology
    Industry
Annual
Quarterly
12/31/2025
Income Statement
Total Operating Revenue
39,990
N/A
Cost of Revenue
N/A
N/A
Gross Profit
39,990
N/A
Sales and Marketing Expense
N/A
N/A
Research and Development Expense
-3.6M
N/A
Depreciation and Amortization Expense
1.1M
N/A
Total Operating Expenses
58.3M
N/A
Operating Profit
-58.2M
N/A
Interest Income
327,582
N/A
Interest Expense
-2.5M
N/A
Interest Income and Expense and Net
-2.2M
N/A
Total Nonoperating Income and Expense
2.5M
N/A
Income before Taxes
-58.2M
N/A
Income Taxes
N/A
N/A
Extraordinary Items
N/A
N/A
Net Income
-62.1M
N/A
Net Income from Continuing Operations Applicable to Common
-62.1M
N/A
Basic EPS and Net Income
-3.20
N/A
Diluted EPS and Net Income
-3.20
N/A
Basic Weighted Average Shares
19.4M
N/A
Diluted Weighted Average Shares
19.4M
N/A
Balance Sheet
Cash and Cash Equivalents
58,729
N/A
Short-Term Investments
N/A
N/A
Cash and Cash Equivalents and Short-Term Investments
58,729
N/A
Total Current Assets
1.4M
N/A
Accumulated Depreciation
N/A
N/A
Property and Plant and Equipment and Net
N/A
N/A
Total Long-Term Assets
47,177
N/A
Total Assets
2.8M
N/A
Income Taxes Payable
N/A
N/A
Total Short-Term Debt
6.7M
N/A
Total Current Liabilities
20.0M
N/A
Total Long-Term Debt
N/A
N/A
Total Long-Term Liabilities
652,495
N/A
Total Liabilities
20.3M
N/A
Retained Earnings
-112.8M
N/A
Total Stockholders Equity
-17.5M
N/A
Total Shares Outstanding
22.0M
N/A
Cash Flow
Cash from Operating Activities
-20.4M
N/A
Capital Expenditures
500,000
N/A
Cash from Investing Activities
-500,000
N/A
Dividends Paid
N/A
N/A
Cash from Financing Activities
20.9M
N/A
Financials Ratio
Gross Margin
N/A
N/A
Operating Margin
N/A
N/A
Return on Assets
N/A
N/A
Return on Equity
N/A
N/A
Revenue Growth
N/A
N/A
Current Ratio
N/A
N/A
Cash Ratio
N/A
N/A
Debt-to-Equity Ratio
N/A
N/A
Debt-to-Assets Ratio
N/A
N/A

Earnings & Revenue History

Debt-to-Assets

Cash Flow